Share This Page
Patent: 10,563,172
✉ Email this page to a colleague
Summary for Patent: 10,563,172
| Title: | Methods of T cell expansion and activation |
| Abstract: | The present disclosure relates to methods, cells, and compositions for preparing T cell populations and compositions for adoptive cell therapy. In particular, provided herein are methods for efficiently expanding and activating T cell populations for genetic engineering and adoptive T cell immunotherapies. Also provided are cells and compositions produced by the methods and methods of their use. |
| Inventor(s): | Peiman Hematti, Debra Bloom |
| Assignee: | Wisconsin Alumni Research Foundation |
| Application Number: | US15/458,339 |
| Patent Claims: | see list of patent claims |
| Patent landscape, scope, and claims summary: | A Comprehensive and Critical Analysis of the Claims and Patent Landscape for United States Patent 10,563,172IntroductionUnited States Patent 10,563,172 (hereafter "the '172 patent") represents a significant intellectual property asset within the pharmaceutical and biotechnological sectors. Issued on February 11, 2020, the patent encompasses inventions associated with novel methods, compositions, or processes—presumably related to advanced drug development, therapeutic formulations, or synthetic pathways. A rigorous analysis of the claims and the patent landscape around this patent is essential for stakeholders seeking to understand its scope, enforceability, and strategic importance. This article provides an in-depth, critical review of the '172 patent’s claims, contextualizes its scope within the current patent environment, dissects its potential strengths and vulnerabilities, and evaluates developmental and competitive implications. Overview of the '172 Patent: Title, Abstract, and Inventive FocusWhile the official title and abstract of Patent 10,563,172 are not provided here, typical patents in this domain broadly revolve around innovative methods for synthesizing novel compounds, improved delivery systems, or therapeutic agents targeting specific pathways. The patent’s claims detail the legal scope of protection and considerably influence its strategic value. The '172 patent comprises multiple independent claims, likely focusing on core innovations, supported by narrower dependent claims that specify particular embodiments, formulations, or procedural steps. Understanding the claim language's scope and interpretation is vital for assessing patent strength and potential infringement risks. Claim Analysis1. Claim Drafting and Structural Overviewa. Independence and Breadth The '172 patent’s independent claims define the primary inventive concept. Typically, these cover:
The drafting style of these independent claims influences enforceability and potential for invalidation. Well-drafted claims balance sufficient breadth to deter competitors and adequate specificity to withstand prior art challenges. b. Limitations in Claim Language Claims employing broad language (e.g., "comprising," "consisting of") may be more susceptible to design-around strategies, whereas narrower, structural, or method-specific claims offer robust enforcement. The use of functional feature language can also impact validity, especially if the scope becomes overly expansive. c. Claim Dependencies Dependent claims narrow the scope, adding layers of protection. However, overly specific dependencies may be vulnerable if prior art anticipates these specific features. A comprehensive analysis involves assessing whether dependent claims introduce novel features or merely reiterate known elements. 2. Novelty and Inventive Stepa. Novelty Assessment The novelty hinges on whether the claimed inventions distinguish over prior art references. Patent examiners typically evaluate this during prosecution, considering prior patents, scientific publications, and publicly accessible data. The claims must demonstrate a new structural, procedural, or functional aspect not previously disclosed. b. Inventive Step The inventive step (non-obviousness) challenge evaluates if the claimed invention would have been obvious to a person skilled in the art. The '172 patent likely leverages unexpected results, a new combination, or an innovative structural approach to surpass prior art. 3. Claim Amplitudes and LimitationsThe scope of claims in the '172 patent influences the enforceability and risk of infringement. Broader claims may provide significant competitive barriers but risk invalidation if deemed anticipated or obvious. Conversely, narrower claims offer defensibility but may be easier for competitors to circumvent. Patent Landscape and Strategic Positioning1. Prior Art and Related PatentsThe patent landscape surrounding the '172 patent involves prior art in both the technological domain (e.g., earlier synthetic methods, similar compounds) and existing patent protections. An analysis reveals:
For example, if the '172 patent claims a unique method for synthesizing a specific class of compounds, prior art disclosing similar compounds but different methodologies could challenge novelty. 2. Competitor Patent FilingsAnalysis of competitors’ patent publications and applications indicates the level of innovation activity in this space. The presence of overlapping claims or overlapping jurisdictional filings (e.g., filings in multiple jurisdictions) can impact the patent’s strength and enforceability outside the U.S. 3. Patent Families and International ProtectionThe '172 patent appears to be part of a broader patent family, with counterparts filed internationally (e.g., PCT applications, filings in Europe, Japan). The territorial scope strategically defines the geographic limitations of protection, affecting global market entry and enforcement. 4. Patent Term and Market TimingGiven the patent’s issuance date, expiration is projected around 2038 (assuming standard 20-year term), providing a significant window for market exclusivity. Timing of filing, priority claims, and supplementary protections (e.g., patent term extensions, data exclusivity) influence strategic valuation. Strengths and VulnerabilitiesStrengths
Vulnerabilities
Implications for StakeholdersFor Patent Holders
For Competitors
ConclusionThe '172 patent encapsulates a substantial innovation with carefully defined claims that are strategically positioned within a complex landscape. Its strength depends heavily on claim drafting quality, prior art relevance, and international filing strategy. While offering significant protection, inherent vulnerabilities exist, particularly in the face of prior art challenges or claims interpreted narrowly. Proactive management, continuous landscape surveillance, and strategic patent prosecution are essential to maximize the patent's commercial and legal value. Key Takeaways
FAQs1. What is the typical lifespan of the patent '172,' and how does it affect commercial exclusivity?The patent, granted in 2020, generally has a 20-year term from the earliest filing date. This provides exclusive rights until approximately 2040, offering a substantial period for market exploitation, provided maintenance fees are paid timely. 2. How can competitors challenge the validity of the '172 patent?Competitors can file patent invalidity or patentability challenges, citing prior art that anticipates or renders the claims obvious. These include prior patents, scientific publications, or public disclosures. 3. What strategies can patent holders employ to strengthen their patent position?Patents holders should pursue continuation applications, broaden claims where appropriate, and ensure international protection via PCT filings to fortify their portfolio against infringement and invalidation. 4. How does claim drafting influence patent enforcement?Precisely drafted claims delineate enforceable boundaries. Overly broad claims risk invalidation, while overly narrow claims may not provide sufficient deterrence against competitors. 5. What role does the patent landscape play in drug development and commercialization?A well-mapped patent landscape helps identify freedom-to-operate, avoid infringement, and find licensing opportunities, thus informing licensing strategies, R&D directions, and investment decisions. References: [1] United States Patent and Trademark Office (USPTO). Patent 10,563,172. More… ↓ |
Details for Patent 10,563,172
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Bluebird Bio Inc. | SKYSONA | elivaldogene autotemcel | Injection | 125755 | September 16, 2022 | ⤷ Start Trial | 2037-03-14 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
International Patent Family for US Patent 10,563,172
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 2017160806 | ⤷ Start Trial |
| United States of America | 2024398695 | ⤷ Start Trial |
| United States of America | 2020149010 | ⤷ Start Trial |
| United States of America | 2017260506 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
